Mesa Laboratories, Inc. — Earnings Quality Grade F
MLAB · Technology
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 64 days, change -2 days YoY
AR growth 7.5% vs revenue growth 11.5%
Revenue 11.5%, CFFO 6.1%. Cash follows revenue
Expense Quality
Inventory -22.4% vs COGS 8.6%. Normal
CapEx growth 75.3% is >2x revenue growth 11.5%
SG&A/Gross Profit = 76.2%, exceeds 70%
Gross margin 62.6%, change +1.0pp. Stable
Cash Flow Quality
CFFO/NI = -23.71. Below 1.0
FCF $0.0B, FCF/NI = -21.43
Accruals ratio = -11.3%. Low accruals
Cash $0.0B covers only 15% of debt $0.2B
Balance Sheet Health
Goodwill+Intangibles $0.3B = 174% of equity. Over 50%
Debt/EBITDA = 4.3x (>4x). Interest coverage = 1.4x (<2x). Financial stress
Other assets grew 73.9% vs revenue 11.5%
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -5% YoY. Normal
Manipulation Score
M-Score = -2.89 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25